Literature DB >> 19608866

IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma.

Jennifer Dien Bard1, Pascal Gelebart, Mona Anand, Zoulika Zak, Samar A Hegazy, Hesham M Amin, Raymond Lai.   

Abstract

Interleukin (IL)-21 has been reported to both stimulate cell growth and promote survival in benign lymphoid cells and several types of hematopoietic neoplasms. It induces JAK3/STAT3 signaling, a biologically important cellular pathway activated in most cases of anaplastic lymphoma kinase (ALK)-expressing anaplastic large cell lymphoma (ALK(+)ALCL). Therefore, we hypothesize that IL-21 may contribute to JAK3/STAT3 activation and cell growth in ALK(+)ALCL. By reverse transcription-PCR, we found consistent expression of IL-21 receptor (IL-21R) in all ALK(+)ALCL cell lines and frozen tumors examined. IL-21 was also consistently expressed in ALK(+)ALCL tumors, although its mRNA was detectable in only one of three cell lines tested. By immunohistochemistry, we examined 10 paraffin-embedded ALK(+)ALCL tumors; all cases were positive for both IL-21 and IL-21R in these neoplastic cells. IL-21 signaling is biologically significant in ALK(+)ALCL since the addition of recombinant IL-21 enhanced the activation of JAK3/STAT3 and significantly increased cell growth in ALK(+)ALCL cell lines. However, small interfering RNA down-regulation of IL-21R significantly decreased both STAT3 activation and cell growth. IL-21R expression is not linked to nucleophosmin-ALK since forced expression of nucleophosmin-ALK and small interfering RNA down-regulation of nucleophosmin-ALK did not significantly change the expression of either IL-21R or IL-21. Our findings thus support the enhancement of JAK3/STAT3 activation and cell growth in ALK(+)ALCL via IL-21 signaling. These results further support the concept that constitutive activation of STAT3 in these tumors is multifactorial.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19608866      PMCID: PMC2716977          DOI: 10.2353/ajpath.2009.080982

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  51 in total

1.  Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma.

Authors:  Yajun Han; Hesham M Amin; Bevin Franko; Christine Frantz; Xinzhe Shi; Raymond Lai
Journal:  Blood       Date:  2006-07-06       Impact factor: 22.113

Review 2.  Pathobiology of ALK+ anaplastic large-cell lymphoma.

Authors:  Hesham M Amin; Raymond Lai
Journal:  Blood       Date:  2007-05-22       Impact factor: 22.113

Review 3.  STATs in oncogenesis.

Authors:  T Bowman; R Garcia; J Turkson; R Jove
Journal:  Oncogene       Date:  2000-05-15       Impact factor: 9.867

Review 4.  STAT signaling in the pathogenesis and treatment of leukemias.

Authors:  T S Lin; S Mahajan; D A Frank
Journal:  Oncogene       Date:  2000-05-15       Impact factor: 9.867

5.  The molecular basis of IL-21-mediated proliferation.

Authors:  Rong Zeng; Rosanne Spolski; Esther Casas; Wei Zhu; David E Levy; Warren J Leonard
Journal:  Blood       Date:  2007-01-18       Impact factor: 22.113

6.  IL-21 is expressed in Hodgkin lymphoma and activates STAT5: evidence that activated STAT5 is required for Hodgkin lymphomagenesis.

Authors:  Ferenc A Scheeren; Sean A Diehl; Laura A Smit; Tim Beaumont; Marianne Naspetti; Richard J Bende; Bianca Blom; Kennosuke Karube; Koichi Ohshima; Carel J M van Noesel; Hergen Spits
Journal:  Blood       Date:  2008-02-22       Impact factor: 22.113

7.  Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha.

Authors:  Björn Lamprecht; Stephan Kreher; Ioannis Anagnostopoulos; Korinna Jöhrens; Giovanni Monteleone; Franziska Jundt; Harald Stein; Martin Janz; Bernd Dörken; Stephan Mathas
Journal:  Blood       Date:  2008-08-06       Impact factor: 22.113

8.  Proteome-wide identification of novel binding partners to the oncogenic fusion gene protein, NPM-ALK, using tandem affinity purification and mass spectrometry.

Authors:  Fang Wu; Peng Wang; Leah C Young; Raymond Lai; Liang Li
Journal:  Am J Pathol       Date:  2009-01-08       Impact factor: 4.307

9.  High IL-21 receptor expression and apoptosis induction by IL-21 in follicular lymphoma.

Authors:  Norihiko Akamatsu; Yasuaki Yamada; Hiroo Hasegawa; Koki Makabe; Ryutaro Asano; Izumi Kumagai; Ken Murata; Yoshitaka Imaizumi; Kunihiro Tsukasaki; Kazuto Tsuruda; Kazuyuki Sugahara; Sunao Atogami; Katsunori Yanagihara; Shimeru Kamihira
Journal:  Cancer Lett       Date:  2007-07-10       Impact factor: 8.679

10.  IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production.

Authors:  Jonathan M Coquet; Konstantinos Kyparissoudis; Daniel G Pellicci; Gurdyal Besra; Stuart P Berzins; Mark J Smyth; Dale I Godfrey
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

View more
  27 in total

1.  A novel role for IL-22R1 as a driver of inflammation.

Authors:  Ram Savan; Adelle P McFarland; Della A Reynolds; Lionel Feigenbaum; Karthika Ramakrishnan; Megan Karwan; Hidekazu Shirota; Dennis M Klinman; Kieron Dunleavy; Stefania Pittaluga; Stephen K Anderson; Raymond P Donnelly; Wyndham H Wilson; Howard A Young
Journal:  Blood       Date:  2010-10-22       Impact factor: 22.113

2.  β-catenin is constitutively active and increases STAT3 expression/activation in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.

Authors:  Mona Anand; Raymond Lai; Pascal Gelebart
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

3.  Exploring the IL-21-STAT3 axis as therapeutic target for Sézary syndrome.

Authors:  Leslie van der Fits; Jacoba J Out-Luiting; Cornelis P Tensen; Willem H Zoutman; Maarten H Vermeer
Journal:  J Invest Dermatol       Date:  2014-04-22       Impact factor: 8.551

4.  Elevated follicular helper T cells and expression of IL-21 in thyroid tissues are involved in the pathogenesis of Graves' disease.

Authors:  Jin Zhang; Meng Ren; Hua Zeng; Ying Guo; Zhenwu Zhuang; Zhimei Feng; Haiyan Yan; Mingtong Xu; Weiwen Liang; Chuan Yang; Hua Cheng; Helin Ding; Li Yan
Journal:  Immunol Res       Date:  2015-06       Impact factor: 2.829

5.  The tyrosine 343 residue of nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) is important for its interaction with SHP1, a cytoplasmic tyrosine phosphatase with tumor suppressor functions.

Authors:  Samar A Hegazy; Peng Wang; Mona Anand; Robert J Ingham; Pascal Gelebart; Raymond Lai
Journal:  J Biol Chem       Date:  2010-04-27       Impact factor: 5.157

6.  Janus Kinase 3, a Novel Regulator for Smooth Muscle Proliferation and Vascular Remodeling.

Authors:  Yung-Chun Wang; Xiao-Bing Cui; Ya-Hui Chuang; Shi-You Chen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-05-04       Impact factor: 8.311

7.  Interleukin-21 is associated with disease activity in patients with Graves' disease.

Authors:  Jin Zhang; Hua Zeng; Meng Ren; Haiyan Yan; Mingtong Xu; Zhimei Feng; Weiwen Liang; Chuan Yang; Hua Cheng; Helin Ding; Li Yan
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

8.  The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update.

Authors:  Raymond Lai; Robert J Ingham
Journal:  Ther Adv Hematol       Date:  2013-04

9.  New developments in the pathology of malignant lymphoma: a review of the literature published from January to August 2009.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2009-09-26       Impact factor: 0.196

Review 10.  Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma.

Authors:  Fabrizio Tabbò; Maurilio Ponzoni; Raul Rabadan; Francesco Bertoni; Giorgio Inghirami
Journal:  Curr Opin Hematol       Date:  2013-07       Impact factor: 3.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.